Lazard Asset Management
ANIX icon

Lazard Asset Management’s Anixa Biosciences ANIX Stock Holding History

Lazard Asset Management’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50
Closed – – 2255
2024
Q2 		$0 Sell
50
-1,144
-96% -$3.24K ﹤0.01% 2221
2024
Q1 		$3K Buy
+1,194
New +$4.76K ﹤0.01% 1914

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MWM
Mission Wealth Management Santa Barbara, California $4.86B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lazard Asset Management's ANIX Position: Q3 2024 in Review

Lazard Asset Management sold out of Anixa Biosciences (ANIX) in Q3 2024, closing a stake of 50 shares.

Lazard Asset Management first reported a position in ANIX in Q1 2024 and held it in 2 quarters. The position peaked at $3K in Q1 2024. 58 funds tracked by Wall St. Rank hold ANIX as of Q3 2024.

  • Lazard Asset Management reported no remaining Anixa Biosciences position as of Q3 2024 after selling out during the quarter.
  • Lazard Asset Management sold 50 Anixa Biosciences shares in Q3 2024.
  • Lazard Asset Management first reported a position in Anixa Biosciences in Q1 2024 and held it in 2 quarters.
  • Lazard Asset Management's Anixa Biosciences position peaked at $3K in Q1 2024.
  • 58 funds tracked by Wall St. Rank held Anixa Biosciences as of Q3 2024.

Based on Lazard Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.